^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Melanotransferrin inhibitor

    Related drugs:
    18d
    SGNBB228-001: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=41, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Terminated; The trial was terminated for strategic reasons. The decision was not based on any safety concerns.
    Trial termination
    |
    PF-08046049
    7ms
    SGNBB228-001: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    PF-08046049
    over1year
    SGNBB228-001: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Active, not recruiting | N=275 --> 41 | Trial completion date: Apr 2028 --> Oct 2025 | Trial primary completion date: Apr 2027 --> Sep 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    PF-08046049
    over1year
    SGNBB228-001: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=275, Recruiting, Seagen Inc. | Trial completion date: Nov 2027 --> Apr 2028 | Trial primary completion date: Nov 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    PF-08046049